Retrospective study of 39 pts w/ MDA5 + DM-ILD Rx w baricitinib. 31 (79.5%) had improvement in Gottron’s, heliotrope, dyspnea, HRCT score, ferritin, LDH, steroid dose & 6 mo survival (87% vs. 70%, p = 0.047). https://t.co/RCTbBsCkeV https://t.co/dF8I0gF4Dy
Links:
Baricitinib could improve the prognosis of anti-MDA5 antibody positive dermatom…
https://buff.ly/ENWEQsl
Nov-29-2025
